NP方案联合恩度治疗复治晚期NSCLC的近期疗效与CEA水平  

Serum CEA markers detection and effects of the NP regimen and rh-endostatin combination on advanced or relapsed non-small cell lung cancer

作　　者：李青峰[1] 赵前锋[1] 张娟[1] 龚先齐[1] 

机构地区：[1]华中科技大学同济医学院附属襄樊医院,湖北襄樊441021

出　　处：《海南医学院学报》2010年第1期57-59,共3页Journal of Hainan Medical University

基　　金：海南医学院科研基金资助学报项目(0020100007)~~

摘　　要：目的:检测患者血清CEA水平变化,评价重组人血管内皮抑制素联合NP方案治疗复治的晚期非小细胞肺癌(NSCLC)的近期疗效。方法:采用放射免疫技术对10例复治晚期的非小细胞肺癌患者,检测重组人血管内皮抑素联合NP方案治疗前.后血清CEA水平。结果:血清CEA水平在重组人血管内皮抑素联合NP方案治疗后为(60.27±11.25)ng/mL比治疗前(345.46±10.04)ng/mL低,差异有统计学意义(P<0.01)。结论:重组人血管内皮抑素联合NP方案能明显提高复治晚期的NSCLC患者临床受益率。检测肿瘤标记物CEA水平有助于对重组人血管内皮抑制素联合NP方案治疗复治晚期非小细胞肺癌的近期治疗反应判断。Objective： To investigate the changes of serum CEA level and to evaluate effects of the NP regimen and rh-endostatin combination on advanced or relapsed non-small cell lung cancer. Methods： Using immunoradiometric assay （IRMA） to detect the serum CEA levels in 10 advanced or relapsed NSCI.C cases before and after the treatment of NP regimen and rh-endostatin combination. Results： After the treatment of NP regimen and rh-endostatin combination, the serum CEA level was （60.27±11.25） ng/mL, significant lower than （345. 46±10.04） ng/mL before the treatment （P〈0.01）. Conclusion： The NP regimen and rh-endostatin combination can increase the clinical benefit rate（CBR）of NSCI.C patients, detection of serum CEA level can help to evaluate its therapeutic efficacy on advanced or relapsed NSCLC patients.

关 键 词：重组人血管内皮抑制素 NP方案 复发晚期非小细胞肺癌 CEA 

分 类 号：R734.2[医药卫生—肿瘤]